Related Experiment Video
Updated: Aug 18, 2026

Assessment of Vascular Function in Patients With Chronic Kidney Disease
Published on: June 16, 2014
[Hypertension, atherosclerosis and kidney]
A Zuccalà1, S Fiorenza, R Rapanà
1U.O. Nefrologia-Malpighi, Policlinico S.Orsola-Malpighi, Bologna, Italy. azuccala@orsola-malpighi.med.unibo.it
Insights
Patients with end-stage renal disease (ESRD) face significantly higher cardiovascular risk. Even minor kidney dysfunction, like microalbuminuria, elevates this risk through various mechanisms impacting atherosclerosis.
Area of Science:
- Nephrology
- Cardiology
- Vascular Biology
Context:
- Cardiovascular risk is substantially elevated in patients with end-stage renal disease (ESRD).
- Minor renal dysfunctions, including microalbuminuria and elevated serum creatinine (Cr), significantly impact cardiovascular risk.
- Increased cardiovascular risk is observed across diverse populations, from the general public to high-risk patients with heart failure.
Purpose:
- To explore the multifaceted mechanisms linking kidney disease and cardiovascular risk.
- To elucidate the dual role of the kidney as both a contributor to and victim of atherosclerosis.
- To highlight the kidney's potential as a sensor of subclinical cardiovascular damage.
Summary:
- Kidney disease and renal insufficiency contribute to cardiovascular risk by inducing hypertension, dyslipidemia, sympathetic hyperactivity, and renin-angiotensin system activation.
- Moderate to severe renal insufficiency increases vasculotoxic substances (e.g., ADMA, lipoprotein(a), homocysteine), disrupts mineral metabolism, causes anemia, and leads to left ventricular hypertrophy.
- Severe renal insufficiency can precipitate the malnutrition-inflammation-atherosclerosis (MIA) syndrome, while the kidney can also be a victim of atherosclerosis via ischemic nephropathy.
Impact:
- Understanding these links is crucial for developing targeted interventions to mitigate cardiovascular events in renal patients.
- Recognizing the kidney's role can lead to earlier detection and management of cardiovascular disease.
- This research underscores the importance of a holistic approach to patient care, integrating nephrology and cardiology.
Abstract:
Cardiovascular risk is dramatically increased in patients with end-stage renal disease (ESRD). However, even minor dys-functions such as microalbuminuria or a mild increase in serum creatinine (Cr) have a major impact on cardiovascular risk. Increased cardiovascular risk is present in multiple populations, including general populations, patients with moderate risk such as hypertensives, and high-risk patients including patients with heart failure and myocardial necrosis. There are many mechanisms underpinning the increased cardiovascular risk. Regarding atherosclerosis, the kidney can be victim or villain. On the one hand, both kidney disease per se and renal insufficiency can induce vascular damage, thereby increasing cardiovascular risk. Kidney disease without renal insufficiency can cause an increased prevalence in hypertension, dyslipidemia (nephrotic syndrome), sympathetic system hyperactivity, and in renin angiotensin system hyperactivity. A moderate-severe renal insufficiency can induce an increase in many vasculotoxic substances such as ADMA, lipoprotein(a), homocysteine, disturbances in calcium and phosphate metabolism, anemia and left ventricular hypertrophy. A more severe renal insufficiency can induce the ominous malnutrition-inflammation-atherosclerosis (MIA) syndrome. On the other hand, the kidney can be the victim of atherosclerosis. Ischemic nephropathy, caused by atherosclerotic renal artery disease and atheroembolism from abdominal aorta are two examples. Finally, it is important to consider that the kidney, being an organ with a wide vasculature, could be a sophisticated sensor of subclinical cardiovascular damage.
Related Concept Videos
Hypertension II: Pathophysiology
Hypertension and Regulation of Blood Pressure
Hypertension III: Clinical Manifestations and Diagnostic Studies
Hypertension I: Introduction
Antihypertensive Drugs: Angiotensin-Converting Enzyme Inhibitors
Diabetic Nephropathy
